Literature DB >> 12244383

Myasthenic crisis: report of 24 cases.

Lineu Cesar Werneck1, Rosana Herminia Scola, Francisco Manoel Branco Germiniani, Enio A Comerlato, Francisco Marcos Bezerra Cunha.   

Abstract

Myasthenic crisis (MC) is a life-threatening complication of myasthenia gravis (MG) with a high mortality rate. The aim of our study was to review the different therapeutics approaches in the treatment of MC and their impact in the final outcome. We reviewed the medical files of patients diagnosed with MG admitted between February 1993 and October 1997, who developed MC. Sex, mean age, disease's duration, functional scale, symptoms preceding the crisis, crisis therapy in each set and mortality were then analysed. There were 24 patients who developed MC, 21 females and 3 males, with 1 neonatal, 1 congenital sporadic, 17 juvenile/adult, 3 over 50 years and 2 with thymoma. Dysphagia, dysphonia and dysartria were the most common symptoms preceding the crisis. A precipitating factor was elicited in 8 cases and the most common was infection (upper airway infection, urinary tract infection and pneumonia). 16 patients needed a nasogastric tube and 9 had a tracheostomy performed. 24 patients used anticholinesterase drugs, 21 prednisone, 7 immunosuppressive agents, 5 plasmapheresis, 3 human hyperimune gamma immunoglobulin and 12 had thymectomy. A good response was obtained in 13, satisfactory in 7 and there were 4 deaths. We concluded that in spite of all the therapeutics options, there were non statistically significant differences in the outcome of patients that underwent thymectomy and those who did not.

Entities:  

Mesh:

Year:  2002        PMID: 12244383     DOI: 10.1590/s0004-282x2002000400001

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  6 in total

1.  Tako-tsubo cardiomyopathy in a patient with myasthenia gravis crisis: a rare clinical association.

Authors:  Sasidharan Bijulal; Sivadasanpillai Harikrishnan; Narayanan Namboodiri; Valaparambil K Ajitkumar; Deepak Gupta; P S Mathuranath
Journal:  BMJ Case Rep       Date:  2009-02-16

2.  Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Authors:  Mirjana Zdraljevic; Stojan Peric; Marta Jeremic; Dragana Lavrnic; Ivana Basta; Ljiljana Hajdukovic; Dejana R Jovanovic; Ivana Berisavac
Journal:  Neurol Sci       Date:  2022-09-09       Impact factor: 3.830

3.  The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barré syndrome admitted to critical care : an analysis of the Intensive Care National Audit & Research Centre (ICNARC) national United Kingdom database.

Authors:  Maxwell S Damian; Yoav Ben-Shlomo; Robin Howard; Tony Bellotti; David Harrison; Kathryn Griggs; Kathryn Rowan
Journal:  Intensive Care Med       Date:  2013-05-24       Impact factor: 17.440

4.  Predictors of outcome of myasthenic crisis.

Authors:  J Kalita; A K Kohat; U K Misra
Journal:  Neurol Sci       Date:  2014-02-05       Impact factor: 3.307

5.  Clinical profile and outcome of myasthenic crisis in a tertiary care hospital: A prospective study.

Authors:  Sudhir Sharma; Vivek Lal; Sudesh Prabhakar; Ritesh Agarwal
Journal:  Ann Indian Acad Neurol       Date:  2013-04       Impact factor: 1.383

6.  Therapeutic plasma exchange in the treatment of myasthenia gravis.

Authors:  Rajesh Kumar; S Paul Birinder; Sonia Gupta; Gagandeep Singh; Amarjit Kaur
Journal:  Indian J Crit Care Med       Date:  2015-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.